Last reviewed · How we verify

NCT05870215: PRISMA

Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks

Completed Last updated 21 June 2024
What this trial tests

trial testing Visit 1: Clinical exam and questionnaires in Asthma in 78 participants. Completed in 13 June 2024.

Timeline
1 September 2022
Primary endpoint
18 April 2024
13 June 2024

Quick facts

Lead sponsorUniversité de Sherbrooke
StatusCompleted
Study typeOBSERVATIONAL
Enrollment78
Start date1 September 2022
Primary completion18 April 2024
Estimated completion13 June 2024
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Université de Sherbrooke — full company profile →

Who can join

12 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study compares the phenotypic variability (clinical and biological) in treatment response to systemic corticosteroids according to the blood eosinophil count and FeNO in physician-diagnosed ≥12-year-old asthmatics presenting with an asthma attack and healthy controls. Multimodal clinical and translational assessments will be performed on 50 physician-diagnosed, ≥12-year-old asthma patients presenting with an asthma attack and 12 healthy controls. These will include a blood eosinophil count, FeNO, and testing for airway infection (conventional sputum cultures and POC nasopharyngeal swabs). People with asthma will be assessed on day 0 and after a 7-day corticosteroid course, with in-home monitoring performed in between.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA).
    Celis-Preciado C, Leclerc S, Duval M, Cliche DO, et al · · 2025 · cited 15× · PMID 39947666 · DOI 10.1183/13993003.02391-2024
  2. Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): protocol for an observational and translational pilot study.
    Celis-Preciado CA, Leclerc S, Duval M, Cliche DO, et al · · 2023 · cited 8× · PMID 37940357 · DOI 10.1136/bmjresp-2023-001932
  3. Development and validation of a UHPLC-MS/MS method for the quantification of total conjugated 3-bromotyrosine and investigation of its association with asthma severity.
    Gamrani M, Farjallah A, Kpaossou FM, Cliche D, et al · · 2026 · PMID 41997677 · DOI 10.1016/j.aca.2026.345450

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Université de Sherbrooke trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing